Molecular and immunohistochemical analyses of BCL2, KI-67, and cyclin D1 expression in synovial sarcoma

Cancer Genetics and Cytogenetics

Volumn 193, Issue 1, 2009, Pages 1-8

  Krsková, Lenka ^a   Kalinová, Markéta ^a   Břízová, Helena ^a   Mrhalová, Marcela ^a   Sumerauer, David ^a   Kodet, Roman ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN BCL 2; CCND1 PROTEIN, HUMAN; RNA;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CHILD; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SYNOVIAL SARCOMA; AGED; ANALYSIS OF VARIANCE; CELL NUCLEUS; CHEMISTRY; CONNECTIVE TISSUE TUMOR; GENETICS; IMMUNOHISTOCHEMISTRY; INFANT; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE TUMOR;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS; STATISTICS, NONPARAMETRIC;

EID: 67651094040     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2009.03.008     Document Type: Article

References (34)

1. Clark J., Rocques P.J., Crew A.J., Gill S., Shipley J., Chan A.M., Gusterson B.A., and Cooper C.S. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat Genet 7 (1994) 502-508
2. Crew A.J., Clark J., Fisher C., Gill S., Grimer R., Chand A., Shipley J., Gusterson B.A., and Cooper C.S. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J 14 (1995) 2333-2340
3. Nilsson G., Skytting B., Xie Y., Brodin B., Perfekt R., Mandahl N., Lundeberg J., Uhlén M., and Larsson O. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 59 (1999) 3180-3184
4. Inagaki H., Nagasaka T., Otsuka T., Sugiura E., Nakashima N., and Eimoto T. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol 13 (2000) 482-488
5. Lopes de Menezes D.E., Hudon N., McIntosh N., and Mayer L.D. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6 (2000) 2891-2902
6. Dan'ura T., Kawai A., Morimoto Y., Naito N., Yoshida A., and Inoue H. Apoptosis and expression of its regulatory proteins in soft tissue sarcomas. Cancer Lett 178 (2002) 167-174
7. Soini Y., Pääkkö P., and Lehto V.P. Histopathological evaluation of apoptosis in cancer. Am J Pathol 153 (1998) 1041-1053
8. Chen-Levy Z., Nourse J., and Cleary M.L. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 9 (1989) 701-710
9. Pilotti S., Mezzelani A., Azzarelli A., Rilke F., and Pierotti M.A. Bcl-2 expression in synovial sarcoma. J Pathol 184 (1998) 337-339
10. Pezzella F., and Gatter K. What is the value of bcl-2 protein detection for histopathologists?. Histopathology 26 (1995) 89-93
11. Castle V.P., Heidelberger K.P., Bromberg J., Ou X., Dole M., and Nuñez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 143 (1993) 1543-1550
12. Inagaki H., Murase T., Otsuka T., and Eimoto T. Detection of SYT-SSX fusion transcript in synovial sarcoma using archival cytologic specimens. Am J Clin Pathol 111 (1999) 528-533
13. Bijwaard K.E., Aguilera N.S., Monczak Y., Trudel M., Taubenberger J.K., and Lichy J.H. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem 47 (2001) 195-201
14. Rochaix P., Krajewski S., Reed J.C., Bonnet F., Voigt J.J., and Brousset P. In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis. J Pathol 187 (1999) 410-415
15. Staunton M.J., and Gaffney E.F. Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 103 (1995) 300-307
16. Kawauchi S., Fukuda T., Oda Y., Saito T., Oga A., Takeshita M., Yokoyama K., Chuman H., Iwamoto Y., Sasaki K., and Tsuneyoshi M. Prognostic significance of apoptosis in synovial sarcoma: correlation with clinicopathologic parameters, cell proliferative activity, and expression of apoptosis-related proteins. Mod Pathol 13 (2000) 755-765
17. Nakanishi H., Ohsawa M., Naka N., Uchida A., Ochi T., and Aozasa K. Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 54 (1997) 238-244
18. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124 (1994) 1-6
19. Lotem J., and Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 4 (1993) 41-47
20. Hennet T., Bertoni G., Richter C., and Peterhans E. Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. Cancer Res 53 (1993) 1456-1460
21. Mancuso T., Mezzelani A., Riva C., Fabbri A., Dal Bo L., Sampietro G., Perego P., Casali P., Zunino F., Sozzi G., Pierotti M.A., and Pilotti S. Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest 80 (2000) 805-813
22. Noguchi S.I., Ueki T., Kawauchi S., Fukuda T., Matsuura H., Sonoda T., and Tsuneyoshi M. Establishment and characterization of a new synovial sarcoma cell line, SN-SY-1: special reference to bcl-2 protein and SYT-SSX1 hybrid transcripts. Int J Cancer 72 (1997) 995-1002
23. Zalupski M.M., Rankin C., Ryan J.R., Lucas D.R., Muler J., Lanier K.S., Budd G.T., Biermann J.S., Meyers F.J., and Antman K. Adjuvant therapy of osteosarcoma: a phase II trial: Southwest Oncology Group study 9139. Cancer 100 (2004) 818-825
24. Miettinen M., Sarlomo-Rikala M., and Kovatich A.J. Cell-type- and tumour-type-related patterns of bcl-2 reactivity in mesenchymal cells and soft tissue tumours. Virchows Arch 433 (1998) 255-260
25. Barbashina V., Benevenia J., Aviv H., Tsai J., Patterson F., Aisner S., Cohen S., Fernandes H., Skurnick J., and Hameed M. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases. J Cancer Res Clin Oncol 128 (2002) 610-616
26. Hirakawa N., Naka T., Yamamoto I., Fukuda T., and Tsuneyoshi M. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol 27 (1996) 1060-1065
27. Maeda K., Chung Y., Kang S., Ogawa M., Onoda N., Nishiguchi Y., Ikehara T., Nakata B., Okuno M., and Sowa M. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 55 (1998) 145-151
28. Gansauge S., Gansauge F., Ramadani M., Stobbe H., Rau B., Harada N., and Beger H.G. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57 (1997) 1634-1637
29. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., and Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 55 (1995) 975-978
30. Antonescu C.R., Leung D.H., Dudas M., Ladanyi M., Brennan M., Woodruff J.M., and Cordon-Cardo C. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol 156 (2000) 977-983
31. Bartkova J., Lukas J., Strauss M., and Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10 (1995) 775-778
32. Antonescu C.R., Kawai A., Leung D.H., Lonardo F., Woodruff J.M., Healey J.H., and Ladanyi M. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol 9 (2000) 1-8
33. Xie Y., Skytting B., Nilsson G., Gasbarri A., Haslam K., Bartolazzi A., Brodin B., Mandahl N., and Larsson O. SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation. Cancer Res 62 (2002) 3861-3867
34. Shao J., Sheng H., DuBois R.N., and Beauchamp R.D. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem 275 (2000) 22916-22924